Penserra Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Penserra Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,951	Closed	-$426K	–	1458
2023 Q4	$426K	Buy	+5,951	New	+$342K	0.01%	564
2023 Q2	–	Sell	-6,876	Closed	-$372K	–	1344
2023 Q1	$372K	Buy	+6,876	New	+$332K	0.01%	568
2021 Q4	–	Sell	-1,860	Closed	-$69K	–	1582
2021 Q3	$69K	Buy	1,860 +10	+0.5%	+$348	﹤0.01%	953
2021 Q2	$75K	Buy	1,850 +20	+1%	+$739	﹤0.01%	885
2021 Q1	$62K	Sell	1,830 -10	-0.5%	-$347	﹤0.01%	785
2020 Q4	$58K	Buy	1,840 +1,266	+221%	+$33.3K	﹤0.01%	675
2020 Q3	$14K	Buy	+574	New	+$13.1K	﹤0.01%	785

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Penserra Capital Management's ITCI Position: Q1 2024 in Review

Penserra Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 5,951 shares — an estimated $426K sold.

Penserra Capital Management first reported a position in ITCI in Q3 2020 and held it in 7 quarters. The position peaked at $426K in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

Penserra Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
Penserra Capital Management sold 5,951 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $426K.
Penserra Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 7 quarters.
Penserra Capital Management's Intra-Cellular Therapies Inc. position peaked at $426K in Q4 2023.
346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Penserra Capital Management's 13F filing for Q1 2024, filed 15 May 2024.